AlphAIAlphAI — Financial news for AI agents
investing.com$LFMD

Mizuho cuts LifeMD stock price target on revenue miss, GLP-1 delays

Mizuho reduced its price target for LifeMD (LFMD) to $6.00 from $7.00, citing Q3 revenue of $45M, missing estimates of $49M. The company lowered its 2026 revenue run rate to $200M from $250M. LFMD stock is down 30% to $1.66. Mizuho maintains an Outperform rating, expecting positive EBITDA by 2027-2028.

Original reporting
investing.com
Published Nov 13, 2026, 11:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 11:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LFMD
Bearish
high confidence
Mentioned
$LFMD
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LFMDBearishMed
01

Why it matters

The guidance downgrade and price‑target cut signal weaker near‑term performance, but margin expansion may support a longer‑term recovery.

02

Market read

The news directly affects LFMD shareholders and may influence sentiment in the biotech small‑cap space.

03

What to watch

Potential upside from upcoming AT&T channel partnership and 2027 EBITDA positivity.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

LifeMD reported Q3 revenue of $45 M versus $49 M estimate and cut its 2026 year‑end revenue run‑rate to $200 M.

Company-level read

Ticker impact

$LFMDBearishHigh confidence
Context

Mizuho lowered its price target on LifeMD to $6 from $7 after the company reported Q3 revenue miss and reduced 2026 guidance.

Expected impact

likely pressure as the market prices in weaker guidance and lower target

Evidence & confidence

Analyst downgrade combined with a 30% week‑long decline indicates traders may sell on the news.

Market effects

Sector

LifeMD's GLP‑1 revenue challenges may weigh on the broader biotech/weight‑loss drug sector.

Regional

Limited to U.S. small‑cap biotech investors.

Global

Minimal; the story is company‑specific.

Counterpoint

What could challenge this read

If the new in‑house pharmacy improves gross margins, the stock could rebound despite the short‑term miss.

Key entities

  • analyst
    Mizuho

    Lowered LFMD price target to $6.

  • company
    LifeMD Inc.

    Reported revenue miss and reduced guidance.

Read at source← All news

Related articles

$LFMDMed

LifeMD Nov 2026 slides: platform scale grows amid revenue reset

LifeMD (LFMD) presented its investor deck, highlighting revenue growth from $11M in 2019 to an expected $190M in 2026. Q3 revenue missed expectations at $44.6M, and the stock fell 17.59%. The company emphasized its telehealth platform's scale, AI integration, and nationwide pharmacy infrastructure, serving 350,000 active patients. LifeMD reset 2026 guidance to $188M-$191M revenue and negative EBITDA, citing delayed GLP-1 fulfillment and reduced marketing.

investing.com
$LFMDMed

Why is LifeMD stock sliding today?

LifeMD (LFMD) stock fell 9.4% after reporting Q3 2026 revenue of $44.6M, missing estimates of $48.9M. The company cut its full-year revenue outlook to $188M-$191M and widened its EBITDA loss forecast. Additionally, an accounting investigation and securities inquiry weighed on sentiment.

investing.com
$LFMDMed

LifeMD Reports Third Quarter 2026 Results

LifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LifeMD Reports Third Quarter 2026 Results ● Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of approximately $0.4 million, within the Company’s guidance range of negative $1 million to positive $2 million. ● Adjusted EBITDA improved approximately $3

SEC EDGAR 8-K
$LFMDMed

LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?

LifeMD (LFMD) partnered with AT&T to offer free virtual-health memberships to 29 million eligible customers in 11 states, with a nationwide expansion planned for 2027. The $19 monthly fee is waived, but services like visits and prescriptions remain payable. LifeMD aims to convert access into recurring demand for paid care, potentially reducing acquisition costs and benefiting from repeat consultations. The phased rollout allows for measuring enrollment and utilization before expansion.

yahoo.com
$TMed

AT&T Waives $19 LifeMD Fee for 100 Million Wireless and Fiber Customers

AT&T is partnering with LifeMD to waive its $19 monthly membership fee for over 100 million wireless and fiber customers, making it the first carrier to bundle no-cost virtual healthcare access. The rollout begins in 11 states, with the rest following in January 2027. LifeMD (LFMD) provides telehealth services, and AT&T aims to enhance customer retention. AT&T's stock is valued at $29.03 per share, with projected slight earnings declines due to heavy capital spending.

kobaran.com